Sort by
Keyphrases
Multiple Sclerosis
98%
Fracture Risk
92%
Population-based Cohort Study
61%
Hazard Ratio
48%
Insulin
37%
Osteoporotic Fractures
36%
Confidence Interval
31%
Multiple Sclerosis Treatment
30%
Thiazolidinediones
30%
National Health
28%
Health Registers
28%
Hip Fracture
28%
Insulin Analogues
27%
Pharmacoepidemiology
26%
Cancer Risk
24%
Ankylosing Spondylitis
23%
Meta-analysis
23%
Clinical Practice Research Datalink
23%
Adjusted Hazard Ratio
22%
Incidence Rate
20%
Multi-database
20%
Individual Patient Data
19%
Cox Proportional Hazards Model
17%
Population-based
16%
United Kingdom
16%
Database Study
16%
Drug Use
16%
General Practice Research Database
15%
Bladder Cancer
14%
Patients with Parkinson's Disease
14%
Human Insulin
14%
Breast Cancer Risk
14%
Cancer Inpatients
14%
Parkinson Patients
14%
Glargine
13%
Birth Timing
13%
Systematic Literature Review
13%
Antidepressants
12%
Ischemic Heart Disease
12%
Denmark
11%
Antidiabetic Drugs
11%
Odds Ratio
11%
Type 2 Diabetes Mellitus (T2DM)
11%
Retrospective Cohort Study
11%
Netherlands
11%
Patients with Diabetes
10%
Pancreatic Cancer
10%
Systematic Meta-analysis
10%
Epidemiology
10%
UK General Practice
10%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Cohort Study
71%
Diseases
32%
Fragility Fracture
32%
Hip Fracture
31%
Thiazolidinedione
30%
Insulin Analog
27%
Observational Study
26%
Diabetes Mellitus
21%
Malignant Neoplasm
20%
Breast Cancer
20%
Ankylosing Spondylitis
19%
Case-Control Study
15%
Parkinson's Disease
15%
Human Insulin
14%
Recombinant Human Insulin
14%
Comorbidity
13%
Colorectal Carcinoma
12%
Antidepressant
12%
Ischemic Heart Disease
12%
Non Insulin Dependent Diabetes Mellitus
10%
Infection
10%
Insulin Glargine
10%
Human Immunodeficiency Virus Infection
9%
Cataract
9%
Pharmacoepidemiology
9%
Non-Steroidal Anti-Inflammatory Drug
9%
Glucocorticoid
9%
Biguanide
7%
Pancreas Cancer
7%
Acute Heart Infarction
7%
HIV
7%
Mortality Rate
6%
Selective Serotonin Reuptake Inhibitor
6%
Femur Fracture
6%
Risk Evaluation
6%
Breast Tumor
6%
Antidiabetic Agent
6%
Urinary Tract Infection
5%
Metformin
5%
Bladder Cancer
5%
Multiple Fracture
5%
Medicine and Dentistry
Cohort Analysis
44%
Systematic Review
33%
Cancer Risk
32%
Meta-Analysis
28%
Diabetes Mellitus
21%
Ankylosing Spondylitis
19%
Breast Cancer
19%
Malignant Neoplasm
16%
Cohort Effect
15%
Diabetes
14%
Retrospective Cohort Study
14%
Hazard Ratio
13%
Patient with Diabetes
13%
Recombinant Human Insulin
13%
Human Insulin
13%
Colorectal Carcinoma
11%
Case-Control Study
11%
Insulin Treatment
10%
Bladder Cancer
10%
In Vitro
9%
Human Immunodeficiency Virus Infection
9%
Odds Ratio
9%
Patient-Data
9%
Observational Study
8%
Psoriasis
8%
Iridocyclitis
8%
Inflammatory Bowel Disease
8%
Breast Tumor
8%
Proportional Hazards Model
7%
Ischemic Heart Disease
7%
Antidiabetic Agent
7%
Insulin Glargine
6%
Nonsteroid Antiinflammatory Agent
6%
Pancreas Cancer
6%
Patient with Type 2 Diabetes
5%
Maturity Onset Diabetes of the Young
5%
Human Immunodeficiency Virus
5%
Body Mass Index
5%
Glycon
5%
Drug Use
5%
Cancer
5%
Logistic Regression Analysis
5%
